Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab in Uncontrolled Asthma
NCT06932263Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of tozorakimab in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualised rate of severe asthma exacerbations at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06932263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932263.